Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor CellsBenjamin Boyerinas, Jeffrey Schlom, James L. Gulley et al.|Cancer Immunology Research|2015Cited by 456
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid TumorsJulius Strauss, James L. Gulley, Christopher R. Heery et al.|Clinical Cancer Research|2018Cited by 415